Business Description
XORTX Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA98420Q1081
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 273.21 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -33 | |||||
3-Year EPS without NRI Growth Rate | -30.7 | |||||
3-Year FCF Growth Rate | -64.6 | |||||
3-Year Book Growth Rate | 23.8 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.23 | |||||
9-Day RSI | 64.21 | |||||
14-Day RSI | 53.52 | |||||
6-1 Month Momentum % | 9.72 | |||||
12-1 Month Momentum % | -59.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 13.66 | |||||
Quick Ratio | 13.66 | |||||
Cash Ratio | 11.24 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.5 | |||||
Shareholder Yield % | -25.35 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -56.39 | |||||
ROA % | -46.97 | |||||
ROIC % | -323.41 | |||||
ROC (Joel Greenblatt) % | -2447.7 | |||||
ROCE % | -77.78 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.07 | |||||
Price-to-Tangible-Book | 3.65 | |||||
EV-to-EBIT | -0.88 | |||||
EV-to-EBITDA | -0.91 | |||||
EV-to-FCF | -0.71 | |||||
Price-to-Net-Current-Asset-Value | 7.73 | |||||
Price-to-Net-Cash | 30.31 | |||||
Earnings Yield (Greenblatt) % | -113.71 | |||||
FCF Yield % | -63.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return %
Total Annual Return %
XORTX Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -1.836 | ||
Beta | 0.36 | ||
Volatility % | 73.32 | ||
14-Day RSI | 53.52 | ||
14-Day ATR (C$) | 0.251398 | ||
20-Day SMA (C$) | 3.557 | ||
12-1 Month Momentum % | -59.73 | ||
52-Week Range (C$) | 2.65 - 9.99 | ||
Shares Outstanding (Mil) | 2.9 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
XORTX Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
XORTX Therapeutics Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
XORTX Therapeutics Inc Frequently Asked Questions
What is XORTX Therapeutics Inc(TSXV:XRTX)'s stock price today?
When is next earnings date of XORTX Therapeutics Inc(TSXV:XRTX)?
Does XORTX Therapeutics Inc(TSXV:XRTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |